Although patients without other comorbidities tended to take greater advantage of receiving SGLT2 inhibitors and lower gout incidence, our results noted that the benefit of SGLT2 inhibitors in patients with T2DM for lower risk of gout were not significantly different across subgroups. Here, SLC5A2 is linked to gout.